CL2014000759A1 - Composicion para uso en el crecimiento del cerebro y/o desarrollo cognitivo y/o desarrollo psicomotor que comprende al menos un ácido graso poliinsaturado de cadena larga (lc-pufa), al menos un probiótico y una mezcla de oligosacáridos; uso de la composición. - Google Patents

Composicion para uso en el crecimiento del cerebro y/o desarrollo cognitivo y/o desarrollo psicomotor que comprende al menos un ácido graso poliinsaturado de cadena larga (lc-pufa), al menos un probiótico y una mezcla de oligosacáridos; uso de la composición.

Info

Publication number
CL2014000759A1
CL2014000759A1 CL2014000759A CL2014000759A CL2014000759A1 CL 2014000759 A1 CL2014000759 A1 CL 2014000759A1 CL 2014000759 A CL2014000759 A CL 2014000759A CL 2014000759 A CL2014000759 A CL 2014000759A CL 2014000759 A1 CL2014000759 A1 CL 2014000759A1
Authority
CL
Chile
Prior art keywords
composition
development
pufa
probiotic
oligosaccharides
Prior art date
Application number
CL2014000759A
Other languages
English (en)
Spanish (es)
Inventor
Clara Garcia-Rodenas
Kurt Ornstein
Original Assignee
Nesctec S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47019022&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000759(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nesctec S A filed Critical Nesctec S A
Publication of CL2014000759A1 publication Critical patent/CL2014000759A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pediatric Medicine (AREA)
  • Psychology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2014000759A 2011-10-18 2014-03-27 Composicion para uso en el crecimiento del cerebro y/o desarrollo cognitivo y/o desarrollo psicomotor que comprende al menos un ácido graso poliinsaturado de cadena larga (lc-pufa), al menos un probiótico y una mezcla de oligosacáridos; uso de la composición. CL2014000759A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11185600 2011-10-18

Publications (1)

Publication Number Publication Date
CL2014000759A1 true CL2014000759A1 (es) 2014-08-22

Family

ID=47019022

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000759A CL2014000759A1 (es) 2011-10-18 2014-03-27 Composicion para uso en el crecimiento del cerebro y/o desarrollo cognitivo y/o desarrollo psicomotor que comprende al menos un ácido graso poliinsaturado de cadena larga (lc-pufa), al menos un probiótico y una mezcla de oligosacáridos; uso de la composición.

Country Status (16)

Country Link
US (1) US20140271562A1 (cg-RX-API-DMAC7.html)
EP (2) EP3095331A1 (cg-RX-API-DMAC7.html)
CN (1) CN103889238B (cg-RX-API-DMAC7.html)
AU (1) AU2012325060B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014008944B1 (cg-RX-API-DMAC7.html)
CL (1) CL2014000759A1 (cg-RX-API-DMAC7.html)
ES (1) ES2601891T3 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN01468A (cg-RX-API-DMAC7.html)
MX (1) MX350435B (cg-RX-API-DMAC7.html)
MY (1) MY170185A (cg-RX-API-DMAC7.html)
PH (1) PH12014500443A1 (cg-RX-API-DMAC7.html)
PL (1) PL2775852T3 (cg-RX-API-DMAC7.html)
PT (1) PT2775852T (cg-RX-API-DMAC7.html)
RU (1) RU2607458C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013057049A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201403591B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3248605A1 (en) 2009-07-06 2017-11-29 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
DK2708145T3 (en) 2012-09-14 2016-07-18 Abbott Lab Nutritional Compositions for Use in Methods to Modulate Corticosterone Levels in Psychologically Stressed Individuals
EP3704957A1 (en) 2012-09-14 2020-09-09 Abbott Laboratories Methods for increasing brain functionality using 2-fucosyl-lactose
EP2880993A1 (en) * 2013-12-04 2015-06-10 Abbott Laboratories Method of achieving memory and learning improvement by the administration of sialic acid
EP3082473A2 (en) * 2013-12-19 2016-10-26 Nestec S.A. Nutritional composition to reduce metabolic stress in infants
US20150305385A1 (en) * 2014-04-25 2015-10-29 Mead Johnson Nutrition Company Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics
FR3020949B1 (fr) * 2014-05-16 2018-02-09 Ecole Normale Superieure De Lyon Composition permettant de favoriser la croissance juvenile humaine et animale en cas de malnutrition
EP3212012A1 (en) * 2014-10-31 2017-09-06 Nestec S.A. Composition comprising fut2-dependent oligosaccharides and lacto-n-neotetraose for use in promoting brain development and cognition
CN106998775A (zh) * 2014-11-26 2017-08-01 雅培制药有限公司 具有RRR‑α‑生育酚、2’‑岩藻糖基乳糖和益生菌的婴儿配方
WO2016145628A1 (en) * 2015-03-18 2016-09-22 Nestec S.A. Composition comprising siallyllactose for use in enhancing learning skills and memory function
WO2016176484A1 (en) 2015-04-28 2016-11-03 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain
CN107847509B (zh) * 2015-08-04 2021-06-01 雀巢产品有限公司 具有2FL和LNnT的营养组合物
ES2759556T3 (es) 2015-12-15 2020-05-11 Nestle Sa Mezcla de oligosacáricos de la leche humana
US20210205340A1 (en) * 2016-01-26 2021-07-08 Nestec S.A. Compositions comprising sialylated oligosaccharides for use in infants or young children to prevent later in life obesity or related comorbidities and promote a healthy growth
RU2735250C2 (ru) * 2016-01-26 2020-10-29 Сосьете Де Продюи Нестле С.А. КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ 2FL И LNnT, ДЛЯ КОНТРОЛЯ ПОТРЕБЛЕНИЯ ПИЩИ И РОСТА У МЛАДЕНЦЕВ ИЛИ ДЕТЕЙ МЛАДШЕГО ВОЗРАСТА
EP3443969B1 (en) * 2016-04-13 2021-12-22 Meiji Co., Ltd. Use of bifidobacteria for improving developmental quotient in neonates
CN109715169A (zh) 2016-07-28 2019-05-03 方塔拉合作集团有限公司 乳制品和工艺
EP3565421A4 (en) 2017-05-04 2020-07-22 The Board of Trustees of the Leland Stanford Junior University FOOD COMPOSITIONS PROMOTING NEUROLOGICAL DEVELOPMENT AND ASSOCIATED KITS, SYSTEMS AND PROCESSES
EP3624786B1 (en) 2017-05-16 2023-07-05 Ability Pharmaceuticals S.L. A pharmaceutical combination for the treatment of a cancer
WO2018215406A1 (en) * 2017-05-24 2018-11-29 Nestec S.A. A nutritional composition for use to enhance attention and/or reduce impulsivity
WO2019008104A1 (en) * 2017-07-07 2019-01-10 Nestec S.A. FORTIFYING HUMAN MILK
WO2019008105A1 (en) * 2017-07-07 2019-01-10 Nestec S.A. FORTIFYING HUMAN MILK
RU2698564C1 (ru) * 2019-01-09 2019-08-28 Федеральное государственное бюджетное учреждение "Уральский научно-исследовательский институт охраны материнства и младенчества" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ ОММ" Минздрава России) Способ прогнозирования риска развития гипотрофии у детей, родившихся в сроке сверхранних преждевременных родов, к скорригированному возрасту 6 месяцев
WO2022117710A1 (en) 2020-12-04 2022-06-09 Société des Produits Nestlé S.A. Stable aqueous composition for preterm to promote early postnal growth
KR102570073B1 (ko) * 2022-11-17 2023-08-24 (주)에이피테크놀로지 2'-푸코실락토오스를 포함하는 치매 개선 또는 치료용조성물
CN118285505A (zh) * 2024-03-29 2024-07-05 黑龙江飞鹤乳业有限公司 促进大脑发育的营养组合物、食品及配方奶粉
WO2025257135A1 (en) 2024-06-10 2025-12-18 N.V. Nutricia Non-digestible oligosaccharide mixture for infants at risk of brain injury

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0481038B1 (en) 1990-04-16 2002-10-02 The Trustees Of The University Of Pennsylvania Saccharide compositions, methods and apparatus for their synthesis
US5545553A (en) 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US20040048926A1 (en) * 2002-03-15 2004-03-11 Hoffman Dennis Robert Use of docosahexaenoic acid and arachidonic acid to enhance the visual development of term infants breast-fed up to the age of six months
PT1638416E (pt) * 2003-06-23 2013-07-08 Nestec Sa Utilização de uma fórmula nutricional para função de barreira intestinal óptima
CA2532489C (en) * 2003-06-23 2012-12-11 Nestec S.A. Infant or follow-on formula
DE602004006133T3 (de) * 2003-06-30 2014-12-24 Clasado Inc. Neue galactooligosaccharidzusammensetzung und herstellung davon
US20070166411A1 (en) * 2005-12-16 2007-07-19 Bristol-Myers Squibb Company Nutritional supplement containing long-chain polyunsaturated fatty acids
MY146109A (en) 2006-02-10 2012-06-29 Nestec Sa Oligosaccharide mixture
EP1993576B1 (en) 2006-03-07 2015-10-21 Nestec S.A. Synbiotic mixture
US20080003330A1 (en) * 2006-06-30 2008-01-03 Ricardo Rueda Infant formulas for early brain development
MX348901B (es) * 2007-11-26 2017-07-03 Nestec Sa Sistema nutricional adaptado a la edad para infantes.
WO2010115935A1 (en) 2009-04-07 2010-10-14 Glycom A/S Synthesis of 2 ' -o-fucosyllactose
EP2251030A1 (en) 2009-05-12 2010-11-17 Nestec S.A. Lactoferrin and brain health and development in infants
EP2258216A1 (en) * 2009-06-02 2010-12-08 Nestec S.A. Nutritional Composition for Supporting Brain Development and Function of Toddlers
EP2258218A1 (en) 2009-06-02 2010-12-08 Nestec S.A. Nutritional Composition for Supporting Brain Development and Function of Toddlers
CN102481323A (zh) * 2009-07-31 2012-05-30 雀巢产品技术援助有限公司 含有益生菌和所选营养物的用于母乳喂养的婴幼儿或宠物的营养组合物
CN105330705A (zh) * 2010-02-19 2016-02-17 格礼卡姆股份公司 用于制备含n-乙酰乳糖胺的四糖乳糖-n-新四糖(lnnt)的方法
EP2404507A1 (en) 2010-07-08 2012-01-11 Nestec S.A. Array of age-tailored nutritional formula with optimum fat content
RU2013158289A (ru) * 2011-06-08 2015-07-20 Нестек С.А. Питательные композиции, содержащие экзогенные компоненты мембран жировых глобул молока

Also Published As

Publication number Publication date
US20140271562A1 (en) 2014-09-18
PH12014500443A1 (en) 2014-04-14
PT2775852T (pt) 2016-11-08
AU2012325060B2 (en) 2015-11-19
ZA201403591B (en) 2016-01-27
MY170185A (en) 2019-07-09
BR112014008944A2 (pt) 2017-05-02
CN103889238A (zh) 2014-06-25
CN103889238B (zh) 2017-10-13
BR112014008944B1 (pt) 2020-09-15
PL2775852T3 (pl) 2017-02-28
AU2012325060A1 (en) 2014-03-13
ES2601891T3 (es) 2017-02-16
MX2014004716A (es) 2015-02-05
RU2014119844A (ru) 2015-11-27
MX350435B (es) 2017-09-06
WO2013057049A1 (en) 2013-04-25
EP3095331A1 (en) 2016-11-23
EP2775852B1 (en) 2016-08-17
RU2607458C2 (ru) 2017-01-10
EP2775852A1 (en) 2014-09-17
IN2014DN01468A (cg-RX-API-DMAC7.html) 2015-05-22

Similar Documents

Publication Publication Date Title
CL2014000759A1 (es) Composicion para uso en el crecimiento del cerebro y/o desarrollo cognitivo y/o desarrollo psicomotor que comprende al menos un ácido graso poliinsaturado de cadena larga (lc-pufa), al menos un probiótico y una mezcla de oligosacáridos; uso de la composición.
SMT201600218B (it) Batterio per uso come probiotico per applicazioni nutrizionali e mediche
GB2514951C (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
CL2014003165A1 (es) Proceso mejorado para la preparación de treprostinil y derivados del mismo.
PL2925293T3 (pl) Formulacje tetracykliny do stosowania miejscowego, ich przygotowanie i zastosowania
MX338015B (es) Composiciones que comprenden un componente de estabilidad de la vida util.
CL2014003232A1 (es) Formulaciones y métodos para la administración vaginal de antiprogestinas.
HRP20190057T1 (hr) Konjugati kvetiapina s masnom kiselinom, postupak izrade i uporaba istih
CO6990720A2 (es) Composiciones que comprenden galatos y galamidas
BR112014012005A2 (pt) composições, métodos, formulação farmacêutica e artigo
WO2014057362A3 (en) Omega -3 compositions
EP2672273A4 (en) INSPECTION SCHIP AND INSPECTION SCHIPE EQUIPPED WITH THE INSPECTION SCHIP
CO7000763A2 (es) Película estructurada que contiene agente beta-nucleante y método para elaborar la misma
EP2777008A4 (en) DYNAMIC GAME BOOK: EXPERIMENTAL PLATFORM FOR SOCIAL NETWORKS
DK2858986T3 (da) Piperidinderivater som gpr119-agonister
CL2014001385A1 (es) Metodo y composicion para aumentar la proporcion de ingredientes dietarios que son resistentes a la degradacion por los microorganismos del rumen
CL2014002951A1 (es) (r)-nifuratel; formulacion farmaceutica que lo contiene; y proceso para fabricar (r)-nifuratel y (s)-nifuratel.
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
BR112014031513A2 (pt) composição alimentícia concentrada, processo para preparar uma composição alimentícia concentrada e uso da composição
MX2014006574A (es) Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.
SMT201600243B (it) Composizioni farmaceutiche comprendenti anakinra senza citrato
UY4067Q (es) Grafica para producto absorbente
EP2879663C0 (fr) Pastilles a cinetiques multiples de liberation de principes actifs
ES2804473T8 (es) Disposición y procedimiento para la inspección del estado de un vehículo
BR112014014825A8 (pt) composições naturais, de liberação múltipla e de reutilização